Vaxcyte (NASDAQ:PCVX) PT Raised to $129.00 at Jefferies Financial Group

Vaxcyte (NASDAQ:PCVX) had its price target lifted by Jefferies Financial Group from $108.00 to $129.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also recently issued reports on the company. Leerink Partners boosted their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an outperform rating in a research report on Tuesday. BTIG Research raised their price target on shares of Vaxcyte from $98.00 to $160.00 and gave the company a buy rating in a report on Tuesday. Needham & Company LLC lifted their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a buy rating in a report on Tuesday. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Vaxcyte in a report on Thursday, June 20th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of Buy and an average target price of $131.83.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $111.58 on Tuesday. The firm has a market cap of $12.14 billion, a price-to-earnings ratio of -26.07 and a beta of 0.97. Vaxcyte has a 52-week low of $44.20 and a 52-week high of $119.27. The stock has a 50-day simple moving average of $81.80 and a 200-day simple moving average of $73.53.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.12). During the same period in the previous year, the business posted ($0.70) earnings per share. As a group, equities research analysts predict that Vaxcyte will post -4.33 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $36,223,088.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Monday, June 24th. The shares were sold at an average price of $75.64, for a total transaction of $1,134,600.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $36,223,088.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mikhail Eydelman sold 1,667 shares of Vaxcyte stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.37, for a total transaction of $127,308.79. Following the completion of the sale, the senior vice president now owns 30,826 shares of the company’s stock, valued at approximately $2,354,181.62. The disclosure for this sale can be found here. Insiders have sold a total of 85,283 shares of company stock worth $7,271,218 in the last quarter. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank lifted its position in shares of Vaxcyte by 4.2% during the 2nd quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock valued at $284,000 after buying an additional 150 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Vaxcyte by 3.1% in the 2nd quarter. AQR Capital Management LLC now owns 10,860 shares of the company’s stock valued at $820,000 after purchasing an additional 328 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Vaxcyte by 1.7% during the fourth quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after buying an additional 376 shares during the last quarter. Finally, Xponance Inc. increased its holdings in shares of Vaxcyte by 7.2% in the second quarter. Xponance Inc. now owns 6,914 shares of the company’s stock worth $522,000 after buying an additional 465 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.